Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 5
2004 3
2005 2
2006 1
2009 2
2010 5
2011 11
2012 10
2013 4
2014 6
2015 2
2016 3
2017 10
2018 12
2019 12
2020 9
2021 7
2022 11
2023 15
2024 10
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, López-Martínez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP, Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL. Apperloo EM, et al. Among authors: laverman gd. Nat Med. 2025 Jan;31(1):278-285. doi: 10.1038/s41591-024-03327-6. Epub 2024 Oct 25. Nat Med. 2025. PMID: 39455729 Clinical Trial.
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: laverman gd. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.
Gritter M, Wouda RD, Yeung SMH, Wieërs MLA, Geurts F, de Ridder MAJ, Ramakers CRB, Vogt L, de Borst MH, Rotmans JI, Hoorn EJ; on behalf of K onsortium. Gritter M, et al. J Am Soc Nephrol. 2022 Sep;33(9):1779-1789. doi: 10.1681/ASN.2022020147. Epub 2022 May 24. J Am Soc Nephrol. 2022. PMID: 35609996 Free PMC article.
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Beernink JM, et al. Among authors: laverman gd. Diabetes Obes Metab. 2025 Aug;27(8):4415-4426. doi: 10.1111/dom.16478. Epub 2025 May 30. Diabetes Obes Metab. 2025. PMID: 40444388 Free PMC article. Clinical Trial.
A spangled colon.
Raghoo R, Laverman GD, Woittiez AJ, van den Hout JH, de Vries PA. Raghoo R, et al. Among authors: laverman gd. Neth J Med. 2012 Oct;70(8):376-80. Neth J Med. 2012. PMID: 23065988 Free article. No abstract available.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; PRIORITY investigators. Tofte N, et al. Among authors: laverman gd. Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312. doi: 10.1016/S2213-8587(20)30026-7. Epub 2020 Mar 2. Lancet Diabetes Endocrinol. 2020. PMID: 32135136 Free article. Clinical Trial.
Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands.
van Bon AC, Blauw H, Jansen TJP, Laverman GD, Urgert T, Geessink-Mennink J, Mulder AH, Out M, Groote Veldman R, Onvlee AJ, Schouwenberg BJJW, Vermeulen MAR, Diekman MJM, Gerding MN, van Wijk JPH, Klaassen M, Witkop M, DeVries JH. van Bon AC, et al. Among authors: laverman gd. Lancet Digit Health. 2024 Apr;6(4):e272-e280. doi: 10.1016/S2589-7500(24)00002-5. Epub 2024 Mar 4. Lancet Digit Health. 2024. PMID: 38443309 Free article. Clinical Trial.
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group. Wasehuus V, et al. Diabetes Obes Metab. 2025 Jan;27(1):387-393. doi: 10.1111/dom.16037. Epub 2024 Oct 28. Diabetes Obes Metab. 2025. PMID: 39468380 Clinical Trial.
133 results